29.34

3.31% 0.94

After Hours: 29.34

Akero Therapeutics Inc (AKRO)

Overview News Price History Option Chain Financials Why AKRO Down? Discussions Forecast

Akero Therapeutics Inc stock is traded at $29.34, with a volume of 1.48M. It is up +3.31% in the last 24 hours and down -4.23% over the past month. Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Previous Close:

$28.40

Open:

$28.09

24h Volume:

1.48M

Relative Volume:

2.52

Market Cap:

$2.05B

Revenue:

Net Income/Loss:

$-237.22M

P/E Ratio:

-11.46

EPS:

-2.56

Net Cash Flow:

$-212.64M

1W Performance:

+1.56%

1M Performance:

-4.23%

6M Performance:

+34.71%

1Y Performance:

+36.09%

1-Day Range:

$28.09

$29.77

1-Week Range:

$27.35

$31.41

52-Week Range:

$15.32

$37.00

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name

Akero Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

650-487-6488

Address

601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA

Employee

Twitter

@akerotx

Next Earnings Date

2024-11-11

Latest SEC Filings

AKRO's Discussions on Twitter

Compare AKRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKRO Akero Therapeutics Inc	29.34	2.05B	0	-237.22M	-212.64M	-3.78
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Initiated	Citigroup	Buy
Apr-22-24	Resumed	BofA Securities	Neutral
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight
Aug-28-23	Initiated	UBS	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-10-21	Initiated	BofA Securities	Buy
Feb-26-21	Initiated	Guggenheim	Buy
Sep-10-20	Initiated	Morgan Stanley	Overweight
Jul-20-20	Reiterated	H.C. Wainwright	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy
Jul-01-20	Reiterated	H.C. Wainwright	Buy
Mar-02-20	Initiated	H.C. Wainwright	Buy
Feb-10-20	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Evercore ISI	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight
Jul-15-19	Initiated	Jefferies	Buy
Jul-15-19	Initiated	ROTH Capital	Buy

View All

Akero Therapeutics Inc Stock (AKRO) Latest News

Dec 19, 2024

Akero Therapeutics' senior VP Patrick Lamy sells $29,130 in stock By Investing.com - Investing.com Australia

Dec 19, 2024

Dec 18, 2024

Akero Therapeutics' senior VP Patrick Lamy sells $29,130 in stock - Investing.com India

Dec 18, 2024

Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 1,000 Shares of Stock - MarketBeat

Dec 18, 2024

Catriona Yale Sells 9,074 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat

Dec 18, 2024

Akero Therapeutics chief scientific officer sells $118,172 in stock By Investing.com - Investing.com South Africa

Dec 18, 2024

Akero Therapeutics executive sells $264k in stock By Investing.com - Investing.com Canada

Dec 18, 2024

Akero Therapeutics chief scientific officer sells $118,172 in stock - Investing.com

Dec 18, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out - AccessWire

Dec 18, 2024

Akero Therapeutics (NASDAQ:AKRO) Trading Down 4.1%What's Next? - MarketBeat

Dec 18, 2024

State Street Corp Has $71.81 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Dec 18, 2024

Fmr LLC Purchases 26,691 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Dec 18, 2024

Dec 17, 2024

Akero Therapeutics (NASDAQ:AKRO) Shares Up 3.5%Here's What Happened - MarketBeat

Dec 17, 2024

Dec 15, 2024

AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc.AKRO - The Eastern Progress Online

Dec 15, 2024

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect - AccessWire

Dec 15, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Down 9.1% in November - MarketBeat

Dec 15, 2024

Dec 13, 2024

Akero Therapeutics' chief development officer sells $86,519 in stock By Investing.com - Investing.com South Africa

Dec 13, 2024

Akero Therapeutics chief scientific officer sells $148,933 in shares By Investing.com - Investing.com Canada

Dec 13, 2024

Dec 12, 2024

Akero Therapeutics COO sells shares worth $77,067 - Investing.com India

Dec 12, 2024

Akero Therapeutics COO sells shares worth $77,067 By Investing.com - Investing.com South Africa

Dec 12, 2024

Akero Therapeutics executive sells $28,480 in common stock By Investing.com - Investing.com South Africa

Dec 12, 2024

Akero Therapeutics CFO sells $86,735 in stock By Investing.com - Investing.com Canada

Dec 12, 2024

Akero Therapeutics CFO sells $86,735 in stock - Investing.com

Dec 12, 2024

Akero Therapeutics' chief development officer sells $86,519 in stock - Investing.com

Dec 12, 2024

(AKRO) Technical Data - Stock Traders Daily

Dec 12, 2024